Q1 2019 13F Holders as of 31 Mar 2019
-
Type / Class
-
Equity / Ordinary Shares, no par value
-
Shares outstanding
-
182,917,028
-
Total 13F shares
-
29,400,279
-
Share change
-
+5,001,879
-
Total reported value
-
$1,142,135,791
-
Put/Call ratio
-
331%
-
Price per share
-
$38.85
-
Number of holders
-
109
-
Value change
-
+$191,634,667
-
Number of buys
-
82
-
Number of sells
-
26
Institutional Holders of Wave Life Sciences Ltd. - Ordinary Shares, no par value (WVE) as of Q1 2019
As of 31 Mar 2019,
Wave Life Sciences Ltd. - Ordinary Shares, no par value (WVE) was held by
109 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
29,400,279 shares.
The largest 10 holders included
RA CAPITAL MANAGEMENT, LLC, JANUS HENDERSON GROUP PLC, Redmile Group, LLC, BlackRock Inc., PRICE T ROWE ASSOCIATES INC /MD/, BB BIOTECH AG, BOXER CAPITAL, LLC, Partner Fund Management, L.P., WELLINGTON MANAGEMENT GROUP LLP, and Point72 Asset Management, L.P..
This page lists
109
institutional shareholders reporting positions in this security
for the Q1 2019 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.